Author: Liu, Xingjian; Song, Haozhi; Jiang, Jianmin; Gao, Xintao; Yi, Yongzhu; Shang, Yuting; Li, Jialei; Li, Dan; Zeng, Zhen; Li, Yinü; Zhang, Zhifang
                    Title: Self-assembling SARS-CoV-2 nanoparticle vaccines targeting the S protein induces protective immunity in mice  Cord-id: x0axvxno  Document date: 2021_2_7
                    ID: x0axvxno
                    
                    Snippet: The spike (S), a homotrimer glycoprotein, is the most important antigen target in the research and development of SARS-CoV-2 vaccine. There is no doubt that fully simulating the advanced structure of this homotrimer in the subunit vaccine development strategy is the most likely way to improve the immune protective effect of the vaccine. In this study, the preparation strategies of S protein receptor-binding domain (RBD) trimer, S1 region trimer, and ectodomain (ECD) trimer nanoparticles were des
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: The spike (S), a homotrimer glycoprotein, is the most important antigen target in the research and development of SARS-CoV-2 vaccine. There is no doubt that fully simulating the advanced structure of this homotrimer in the subunit vaccine development strategy is the most likely way to improve the immune protective effect of the vaccine. In this study, the preparation strategies of S protein receptor-binding domain (RBD) trimer, S1 region trimer, and ectodomain (ECD) trimer nanoparticles were designed based on ferritin nanoparticle self-assembly technology. The Bombyx mori baculovirus expression system was used to prepare these three nanoparticle vaccines with high expression levels in the silkworm. The immune results of mice show that the nanoparticle vaccine prepared by this strategy can not only induce an immune response by subcutaneous administration but also effective by oral administration. Given the stability of these ferritin-based nanoparticles vaccine, easy-to-use and low-cost oral immunization strategy can make up for the vaccination blind areas caused by the shortage of ultralow-temperature equipment and medical resources in underdeveloped areas. And the oral vaccine is also a very potential candidate to cut off the spread of SARS-CoV-2 in domestic and farmed animals, especially in stray and wild animals.
 
  Search related documents: 
                                Co phrase  search for related documents- absence presence and administration group: 1, 2
- absence presence and administration route: 1
- absence presence and localization signal: 1
- absence presence and long term transmission: 1
- absence presence and low immune: 1
- absence presence and low income: 1, 2, 3, 4, 5, 6
- absence presence and low temperature: 1, 2, 3
- acute respiratory and administration group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute respiratory and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- acute respiratory and localization signal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute respiratory and long term spread: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute respiratory and long term transmission: 1, 2, 3, 4, 5, 6, 7
- acute respiratory and low immune: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
- acute respiratory and low immune dose: 1, 2, 3, 4, 5
- acute respiratory and low income: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute respiratory and low income country: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory and low production cost: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory and low temperature: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
- acute respiratory and luciferase assay system: 1
 
                                Co phrase  search for related documents, hyperlinks ordered by date